drugset / Trial / NCT02237937
Optimizing Antidepressant Treatment by Genotype-dependent Adjustment of Medication According to the ABCB1 Gene
Phase 4
Unknown
80 enrolled
HolsboerMaschmeyer NeuroChemie GmbH
Max-Planck-Institute of Psychiatry · collab
RandomizedSingle-groupDouble-blind
Summary
The study evaluates the ABCB1-genotype dependent efficacy of a quick dose-escalation strategy within 28 days of treatment with approved antidepressants that are known substrates of the P-glycoprotein, an efflux pump of the blood-brain barrier expressed by the ABCB1 gene. Moreover, the study evaluates ABCB1-genotype dependent side-effects of approved antidepressants that are known substrates of the P-glycoprotein, an efflux pump of the blood-brain barrier expressed by the ABCB1 gene.
Timeline
- Start
- 2011-09
- Primary completion
- 2014-12
- Completion
- 2014-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Amitriptyline | Small molecule | 150 mg | — |
| Subject | Amitriptyline | Small molecule | 300 mg | — |
| Subject | Amitriptylinoxide | Small molecule | 150 mg | — |
| Subject | Amitriptylinoxide | Small molecule | 300 mg | — |
| Subject | Citalopram | Small molecule | 40 mg | — |
| Subject | Citalopram | Small molecule | 80 mg | — |
| Subject | Escitalopram | Small molecule | 20 mg | — |
| Subject | Escitalopram | Small molecule | 40 mg | — |
| Subject | Nortriptyline | Small molecule | 150 mg | — |
| Subject | Nortriptyline | Small molecule | 300 mg | — |
| Subject | Paroxetine | Small molecule | 40 mg | — |
| Subject | Paroxetine | Small molecule | 80 mg | — |
| Subject | Sertraline | Small molecule | 100 mg | — |
| Subject | Sertraline | Small molecule | 200 mg | — |
| Subject | Trimipramine | Small molecule | 150 mg | — |
| Subject | Trimipramine | Small molecule | 300 mg | — |
| Subject | Venlafaxine | Small molecule | 225 mg | — |
| Subject | Venlafaxine | Small molecule | 450 mg | — |